Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder

ObjectiveTo investigate relationships between serum neurofilament light chain (sNfL), ubiquitin C-terminal hydrolase L1 (sUCHL1), tau (sTau) and glial fibrillary acidic protein (sGFAP) levels and disease activity/disability in neuromyelitis optica spectrum disorder (NMOSD), and the effects of inebil...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of Neurology, Neurosurgery & Psychiatry Jg. 94; H. 9; S. 757 - 768
Hauptverfasser:	Aktas, Orhan, Hartung, Hans-Peter, Smith, Michael A, Rees, William A, Fujihara, Kazuo, Paul, Friedemann, Marignier, Romain, Bennett, Jeffrey L, Kim, Ho Jin, Weinshenker, Brian G, Pittock, Sean J, Wingerchuk, Dean M, Cutter, Gary, She, Dewei, Gunsior, Michele, Cimbora, Daniel, Katz, Eliezer, Cree, Bruce A
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	England BMJ Publishing Group Ltd 01.09.2023 BMJ BMJ Publishing Group LTD BMJ Publishing Group
Schriftenreihe:	Original research
Schlagworte:	Alzheimer's disease Antibodies, Monoclonal, Humanized - therapeutic use Aquaporin 4 Autoantibodies Biomarkers CLINICAL NEUROLOGY Double-Blind Method Function and Dysfunction of the Nervous System General Neurology Humans Immunoglobulin G Integrative Biomedicine [Topic 3] Intermediate Filaments Mann-Whitney U test Monoclonal antibodies Neurology Neuromyelitis Optica Neuromyelitis Optica - blood Neuromyelitis Optica - drug therapy Proteins RANDOMISED TRIALS Statistical significance United States > US San Francisco California California RANDOMISED TRIALS CLINICAL NEUROLOGY
ISSN:	0022-3050, 1468-330X, 1468-330X
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!